My Note: For those new to this blog, Verisante was formerly known as T-Ray Science, but moved from it's proprietary terahertz platform to a multispectral scanning (Raman spectroscopy) platform. (It has licensed it's terahertz application for cancer detection to Teraview, and other companies.)
http://finance.yahoo.com/news/verisante-readies-commercial-launch-revolutionary-120601248.html
There is an epidemic of skin cancer and one emerging medical device firm is poised to capture a big market position and visibility as they prepare to launch a device which addresses this growing need. Skin cancer is one of the world`s most common cancers, and growing. According to experts, more than 3.5 million skin cancers in over two million people are diagnosed annually and each year there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostate, lung and colon.
Chances are, one in five of those of us reading this report will develop skin cancer in the course of a lifetime.
A Candian based firm, Verisante Technology Inc. (VRS.V) (VRSEF) (VRSEF) (V3T.F) has been getting more tradtional media attention than just about any biotech or medical device manufacturer we have ever focused on. For most American investors, however, the firm has been flying well below the radar screen. It appears that is about to change in a big way.
The firm is led by a dynamic young visionary, CEO Thomas Braun. Braun has led the charge through development, testing and some major regulatory approvals for the Raman spectroscopy technology device, which biochemically analyzes tissue, as a platform for cancer diagnosis.
Currently they have two products, the Verisante Core for lung, colon and cervical cancer detection, currently under development and testing; and the Verisante Aura for skin cancer detection, which is approved for sale in Canada, the EU, and Australia. The Aura is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision. The Aura analyses lesions in less than two seconds and detects melanoma with 99% sensitivity vs. 33.85% for primary clinical diagnosis.
Watch the CNN report on Verisante`s Aura device to get a sense of what differentiates the new product in the market place on the firm`s home page.
For Verisante 2012 is a pivotal year. The Company is at the fore of their transition from a developmental company into a revenue generating product company. The Company had several positive events so far this year, but the success of the balance of the year will signal the transformation of Verisante. As Verisante continues turning expectations into accomplishments, the value of the Company should reflect its ongoing success.
The beginning of 2012 has been fruitful for Verisante. The following are the achievement highlights:
In March the Company announced the Aura clinical study results paper ("Real-time Raman spectroscopy for in vivo skin cancer", was co-authored by Drs. Harvey Lui, Jianhao Zhao, David McLean and Haishan Zeng.) would be published by the prestigious American Association of Cancer Research (AACR). The AACR accelerates progress toward the prevention and cure of cancer by promoting research, education, communication, and collaboration. It is the oldest and largest scientific organization in the world that focuses on every aspect of high-quality, innovative cancer research and its reputation for scientific breadth and excellence attract the premier researchers in the field.
Verisante announced on May 8th that they completed the design and fabrication of the beta version of Verisante Aura(TM). The units are intended for safety and field-testing as a final step prior to the commencement of commercial production later this year.
In March, Verisante signed an exclusive distribution agreement for Canada with Clarion Medical Technologies Inc. Clarion has a current line of products that directly relate to UV damage and skin care treatments, in addition to dermatological products and devices utilizing optical technologies for a variety of other medical applications, making Verisante Aura(TM) a natural addition to this existing product line. "Clinical study results have shown that Verisante Aura(TM) is a device that has the potential to revolutionize the way skin cancer is diagnosed," said Dan Webb, CEO of Clarion. "Clarion is very excited to be the Aura`s exclusive distributor in Canada and to be able to bring this life-saving technology to medical professionals across the country."
Verisante has also received several awards for its science and products in 2012. This illustrates that there is interest in the Company`s products prior to their completion and marketing. Verisante Aura(TM) was recently awarded Popular Science Magazine`s "Best of What`s New Award" for 2011, and Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year`s top ranking Technology and Life Sciences Company on the TSX Venture 50.
With an exciting first have of 2012 nearly gone, Verisante is not slowing down. The second half of the year is full of milestones that will put the Company on the trail towards revenues and earnings. The following are some of the value generating events that Verisante could achieve during the duration of 2012:
Now that Verisante has completed their beta units, which is the go-to-market design for the Aura, the Company is in the process of testing the beta units to make sure the new design performs as the trial units did. The Company expects to complete this performance testing within the next few months.
Verisante`s management has publicly stated that they expect the Aura to begin production in the second half of 2012. Since the Company just completed the design and fabrication of the Aura, and still needs to test them, the fourth quarter 2012 is the most likely time to expect the beginning of production.
Chances are, one in five of those of us reading this report will develop skin cancer in the course of a lifetime.
A Candian based firm, Verisante Technology Inc. (VRS.V) (VRSEF) (VRSEF) (V3T.F) has been getting more tradtional media attention than just about any biotech or medical device manufacturer we have ever focused on. For most American investors, however, the firm has been flying well below the radar screen. It appears that is about to change in a big way.
The firm is led by a dynamic young visionary, CEO Thomas Braun. Braun has led the charge through development, testing and some major regulatory approvals for the Raman spectroscopy technology device, which biochemically analyzes tissue, as a platform for cancer diagnosis.
Currently they have two products, the Verisante Core for lung, colon and cervical cancer detection, currently under development and testing; and the Verisante Aura for skin cancer detection, which is approved for sale in Canada, the EU, and Australia. The Aura is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision. The Aura analyses lesions in less than two seconds and detects melanoma with 99% sensitivity vs. 33.85% for primary clinical diagnosis.
Watch the CNN report on Verisante`s Aura device to get a sense of what differentiates the new product in the market place on the firm`s home page.
For Verisante 2012 is a pivotal year. The Company is at the fore of their transition from a developmental company into a revenue generating product company. The Company had several positive events so far this year, but the success of the balance of the year will signal the transformation of Verisante. As Verisante continues turning expectations into accomplishments, the value of the Company should reflect its ongoing success.
The beginning of 2012 has been fruitful for Verisante. The following are the achievement highlights:
In March the Company announced the Aura clinical study results paper ("Real-time Raman spectroscopy for in vivo skin cancer", was co-authored by Drs. Harvey Lui, Jianhao Zhao, David McLean and Haishan Zeng.) would be published by the prestigious American Association of Cancer Research (AACR). The AACR accelerates progress toward the prevention and cure of cancer by promoting research, education, communication, and collaboration. It is the oldest and largest scientific organization in the world that focuses on every aspect of high-quality, innovative cancer research and its reputation for scientific breadth and excellence attract the premier researchers in the field.
Verisante announced on May 8th that they completed the design and fabrication of the beta version of Verisante Aura(TM). The units are intended for safety and field-testing as a final step prior to the commencement of commercial production later this year.
In March, Verisante signed an exclusive distribution agreement for Canada with Clarion Medical Technologies Inc. Clarion has a current line of products that directly relate to UV damage and skin care treatments, in addition to dermatological products and devices utilizing optical technologies for a variety of other medical applications, making Verisante Aura(TM) a natural addition to this existing product line. "Clinical study results have shown that Verisante Aura(TM) is a device that has the potential to revolutionize the way skin cancer is diagnosed," said Dan Webb, CEO of Clarion. "Clarion is very excited to be the Aura`s exclusive distributor in Canada and to be able to bring this life-saving technology to medical professionals across the country."
Verisante has also received several awards for its science and products in 2012. This illustrates that there is interest in the Company`s products prior to their completion and marketing. Verisante Aura(TM) was recently awarded Popular Science Magazine`s "Best of What`s New Award" for 2011, and Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year`s top ranking Technology and Life Sciences Company on the TSX Venture 50.
With an exciting first have of 2012 nearly gone, Verisante is not slowing down. The second half of the year is full of milestones that will put the Company on the trail towards revenues and earnings. The following are some of the value generating events that Verisante could achieve during the duration of 2012:
Now that Verisante has completed their beta units, which is the go-to-market design for the Aura, the Company is in the process of testing the beta units to make sure the new design performs as the trial units did. The Company expects to complete this performance testing within the next few months.
Verisante`s management has publicly stated that they expect the Aura to begin production in the second half of 2012. Since the Company just completed the design and fabrication of the Aura, and still needs to test them, the fourth quarter 2012 is the most likely time to expect the beginning of production.
No comments:
Post a Comment